Table 3 Other treatments of patients in MEXCOVID study
Treatment received | Oxygen support | |||||
|---|---|---|---|---|---|---|
Antiviral treatment | Antibiotic or antifungal treatment | Corticosteroids treatment | Convalescent plasma transfusion | Before haMSCs-Exo nebulization | After haMSCs-Exo nebulization | |
Patient 1 | Arbidol, ribavirin, IFN-α | Cefoperagone sodium and tazobactam sodium | None | Yes | Nasal cannula | Nasal cannula |
Patient 2 | Arbidol, ribavirin, IFN-α, lopinavir-ritonavir | Cefoperagone sodium and tazobactam sodium, meropenem | Methylprednisolone | Yes | Nasal cannula | Nasal cannula |
Patient 3 | Arbidol, IFN-alpha | None | None | None | Nasal cannula | Nasal cannula |
Patient 4 | Arbidol, oseltamivir | Cefoperagone sodium and tazobactam sodium, meropenem, moxifloxacin | Methylprednisolone | Yes | High-flow nasal cannula | Nasal cannula |
Patient 5 | IFN-α | Cefoperagone sodium and tazobactam sodium, meropenem | Methylprednisolone | Yes | Nasal cannula | Nasal cannula |
Patient 6 | Arbidol, IFN-α | Cefoperagone sodium and tazobactam sodium, | None | None | High-flow nasal cannula | Nasal cannula |
Patient 7 | Ganciclovir | Moxifloxacin, meropenem, fluconazole | None | None | Nasal cannula | Nasal cannula |